Premium
Ultra‐short topical treatment of pityriasis versicolor with 2.5% bifonazole cream
Author(s) -
GALIMBERTI R.L.,
BONING M.,
FLORES V.,
GARCIA A.,
MILICICH R.,
SQUIQUERA H. L.,
CASTRO J.,
STETTENDORF S.
Publication year - 1993
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1993.tb00960.x
Subject(s) - bifonazole , pityriasis , dermatology , medicine , group b , group a , antifungal
Summary The therapeutic efficacy of a preparation containing 2.5% bifonazole was investigated by comparing three different treatment modalities—A, B, and C. Group A used bifonazole only on Day 1, Group B applied the cream on Days 1, 2 and 3, and the Group C on Days 1, 3 and 5. Of the patients in Group A 56% had a negative mycological examination at the end of the study. The results obtained in Groups B and C were not significantly different: 92% of the patients had a negative mycological examination at the end of the study. Electron microscope (EM) studies showed morphological alterations such as loss of cytoplasmic organization with shrinkage and folding of the cell membranes after 1 week of treatment only in Groups B and C. We conclude that 2.5% bifonazole is a highly effective treatment for Pityrosporum ovale infection when applied using a 3‐day schedule.